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MINIREVIEW
Chloroquine Resistance in Plasmodium vivax
J. Kevin Baird*
U.S. Naval Medical Research Center Detachment, Lima, Peru
Emerging resistance to chloroquine (CQ) by Plasmodium
vivax threatens the health of the hundreds of millions of people
routinely exposed to the risk of infection with this organism.
CQ has been the first-line therapy for vivax malaria since 1946
(32, 115). Plasmodium falciparum developed resistance to CQ
in the 1950s (110), and today it occurs globally (91). Resistance
by P. vivax was unknown until 1989, when Australians repatri-
ated from Papua New Guinea failed routine treatment (94).
Subsequent reports affirmed that finding, and CQ-resistant P.
vivax (CRPV) was reported from Indonesia (8, 35, 99, 100,
111). Reports from Myanmar (76, 82) and India (56, 107)
followed. CRPV appeared in travelers from Guyana, South
America (88). However, studies in Thailand (38, 72, 103), the
Philippines (10), and Vietnam (105) revealed only CQ-sensi-
tive P. vivax. Surveys in Indonesia revealed a low frequency of
CRPV in the west (10%) (15, 16, 49, 50, 51, 53, 75) and a
higher risk in the east (45%) (9, 18, 52, 81, 102, 106). This
minireview summarizes the present state of knowledge of
CRPV as a scientific, clinical, and public health problem. It
examines the genesis of CQ therapy for P. vivax and the lab-
oratory and clinical data underpinning the diagnosis of CRPV.
The available data showing the global distribution of CRPV
are listed. Finally, the clinical data on alternative therapies
against CRPV are reviewed.
VIVAX MALARIA AND ANTIMALARIAL THERAPY
Four species in the genus Plasmodium routinely infect hu-
mans. P. vivax infects 80 million people annually and accounts
for most cases of malaria occurring outside Africa (79). It
rarely causes death but inflicts debilitating fever, chills, nausea,
vomiting, and myalgia. The prevalence of P. vivax typically
ranges from 1 to 25% in areas of Asia and the Americas
where the organism is endemic, but it is resurging and now
threatens to reencroach where it had been eradicated (7, 28,
31). The chemotherapeutic management of vivax malaria
therefore represents an issue of importance to global health.
The life cycle of plasmodia defines the chemotherapeutic
strategies. These parasites pass through a complex life cycle
marked by forms of distinct morphology, function, location,
clinical consequence, and susceptibility to antimalarial agents.
Figure 1 illustrates the four families of antimalarial drugs de-
fined on the basis of their activities against specific stages in the
life cycle. CQ is a blood schizonticide against both P. vivax and
P. falciparum. Its activity as a gametocytocide within therapeu-
tic ranges is nonexistent against P. falciparum gametocytes but
is potent against P. vivax gametocytes. CQ alone exerts no
known sporonticidal or tissue schizonticidal activity.
Relapse is an important aspect of the P. vivax life cycle
bearing upon chemotherapy and its assessment. Relapse refers
to clinical malaria caused by parasites in the bloodstream orig-
inating from dormant liver stages called hypnozoites seeded by
sporozoites from infectious anopheline mosquitoes (Fig. 1).
Relapse may occur weeks to years following the primary epi-
sode of parasitemia and clinical disease. Tissue schizonticides,
like primaquine, prevent relapse by killing the stages of the
organism in the liver. When a parasitemia reappears after
blood schizonticidal therapy, it may be a relapse from the liver,
a reinfection by a mosquito, or a recrudescence originating
from asexual blood-stage parasites that survived therapy (Fig.
2). The emergence of CQ-resistant P. vivax favors the last
possibility.
CQ THERAPY
Development. The first treatment of humans with CQ oc-
curred in 1936 in four syphilis patients in Dusseldorf, Ger-
many, given P. vivax (32). An accounting of the lost records of
that trial describes CQ as being “too toxic for practical use in
humans.” The Germans investigated sontochin, a methylated
analog, which American forces obtained in liberated Algeria in
May 1943. Patents for sontochin and CQ were discovered in
the United States, and both compounds went to clinical trials.
That work, detailed by Wiselogle (114), proved that CQ was
more effective and better tolerated.
The early nomenclature of CQ includes SN-7618 and “res-
ochin,” identifiers used by the American and German devel-
opers, respectively. The name CQ was formally registered in
the United States in March 1946. A month later Loeb et al.
(71) published the seminal paper on the activity of CQ against
falciparum and vivax malaria. They recommended 1.5 g of base
over 48 h for the treatment of acute falciparum or vivax ma-
laria and 0.3 g of base weekly for prophylaxis. These remain the
standards for treatment and prophylaxis.
Standard versus effective therapy. The genesis of recom-
mended therapy constitutes a critical factor now, 60 years later,
in defining resistance by P. vivax. What was the minimally
effective dose? Loeb et al. (71) provided no data, instead pub-
lishing the “Statement Approved by the Board for the Coor-
dination of Malarial Studies.” Most et al. (80) published the
first clinical data in November 1946: several hundred American
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soldiers were treated with 1.0 g over 12 h, 1.5 g over 96 h, or
2.0 g over 7 days. They recommended the use of 1.5 g over 48 h,
a regimen not represented in their work.
In 1947, Gordon et al. (58) reported that only 0.8 g (for 6
days) had good efficacy against vivax malaria in 39 subjects.
Berliner et al. (20) described total doses from 0.3 to 0.6 g as
consistently curing blood-stage P. vivax (McCoy strain) in 10
subjects. However, total doses 0.3 g often failed. Others soon
affirmed the sensitivity of P. vivax to substandard regimens
down to a 0.3-g total adult dose. Hoekenga (65) described 0.6-
or 0.45-g single-dose regimens in Honduras in 1952. Among
100 subjects receiving 0.6 g, only 1 failed the treatment. Among
120 subjects receiving 0.45 g, 5 failed the treatment. In 1950,
Butts (27) reported on 202 patients in Central America treated
with 0.08 to 1.56 g. Failures occurred only among those receiv-
ing 0.3 g. Wilson and Edeson (113) reported on similar
findings from Malaysia; among 62 subjects treated with single
doses of 0.3 to 0.6 g, none failed. According to Harinasuta as
late as 1992 (as cited by Looareesuwan et al. [73]), P. vivax in
Thailand remained sensitive to treatment with a single 0.35-g
dose. The available data suggest a baseline sensitivity compat-
ible with blood-stage cure of P. vivax with 0.3 g of CQ base.
The data from areas of endemicity led to reasoned recom-
mendations for substandard treatments in “immune” popula-
tions (22). There was no need (or reliable evidence) to invoke
immunity as the basis of efficacy. These regimens had superior
efficacies in nonimmune people as well.
RELAPSE
Assessment of the therapeutic effect of CQ requires an un-
derstanding of relapse, which is parasitemia originating from
latent hypnozoites. The risk of relapse varies with geographic
origin. Strains form tropical regions cause relapses more
quickly and more often than strains from temperate regions.
The rates from a variety of studies have been reviewed else-
where (12). The risk of relapse with tropical P. vivax often
exceeds 50% within a month of the primary attack, and mul-
tiple relapses are the rule. Among strains from temperate
regions, the risk of relapse typically ranges from 5 to 25%, and
multiple relapses are rare.
Early clinical trials often used the Chesson strain of P. vivax,
isolated from an American soldier in New Guinea during the
war (45). Quinine therapy against Chesson is carefully consid-
ered here because it provides a basis for understanding how
relapse confounds gauging of the therapeutic response to CQ.
Wiselogle (114) provided a comprehensive review of the activ-
ity of quinine against P. vivax. In the American clinical trials
conducted during World War II, quinine served as the positive
control for therapeutic activity. Shannon, in Wiselogle (114),
explains the rationale as the fact that quinine is eliminated
within 12 h, and thus, a relapse uninhibited by lingering drug is
allowed. Shannon further explains the certainty that quinine
cured the blood; subjects challenged by blood inoculation and
given 12 g of quinine over 12 days were cured without recur-
rence.
The Chesson sporozoite-challenged subjects treated with
quinine represent, as they did 60 years ago, the key to gauging
the therapeutic response to CQ by P. vivax. Figure 3 illustrates
the relapse rates after quinine treatment. Relapse occurred no
sooner than 17 days after the primary attack (5 days after
quinine treatment). The median time to relapse was 22 days
after the primary attack, and 60% had relapses by 30 days.
However, a relapse before 17 days is possible; people harbor-
ing multiple broods of hypnozoites accumulated over months
or years of exposure may have a relapse at any time. Figure 1
nonetheless suggests that a relapse before 17 days is unlikely
among patients experiencing a primary attack after a brief
exposure.
RELAPSE AFTER CQ TREATMENT
In the 1940s recurrent parasitemia after effective CQ ther-
apy defined the timing and the risk of relapse for CQ-sensitive
FIG. 1. Schematic representing the life cycle of plasmodia and the
four families of antimalarial agents. Sporontocidal agents kill forms in
the mosquito, including infectious sporozoites. Tissue schizonticides
kill parasites developing (schizonts) or quiescent (hypnozoites) in the
liver. Blood schizonticides kill the asexual blood forms (trophozoites
and schizonts) that cause clinical malaria. The gametocytocides kill or
sterilize the sexual forms (gametocytes) that infect mosquitoes.
FIG. 2. The three paths to recurrent parasitemia for malarias
caused by P. vivax and P. ovale. Sporozoites from mosquitoes reinfect
the livers of humans, which yields merozoites that infect blood. Some
sporozoites develop to quiescent hypnozoites in the liver and later
cause relapse. Subpatent trophozoites in blood cells mature to schi-
zonts that rupture and release merozoites that infect the blood and
cause a recrudescence.
4076 MINIREVIEW ANTIMICROB. AGENTS CHEMOTHER.
 
P. vivax. Figure 3 illustrates those data. The risk of relapse
begins after 35 days, and the rate climbs to 58% by 60 days.
What explains the dramatic difference with relapse after qui-
nine treatment? Neither drug alone affects liver stages. The
explanation for the difference between the two plots consti-
tutes the rational basis for a clinical diagnosis of resistance.
Figure 3 reveals that the challenge of a relapse commences
at 17 days and that 60% of patients have relapses by 35 days
(after quinine treatment). The CQ lingering in the blood-
stream for up to 35 days after therapy prevents the recurrent
parasitemias of relapse. CQ-sensitive parasites attempting de-
velopment in the bloodstream at 35 days encounter drug levels
below the minimal effective concentration (MEC) and relapse
occurs. If this interpretation is accurate, standard therapy
should result in drug levels close to the MEC at 35 days. Data
from other sources confirm this. Berliner et al. (20) measured
the MECs for P. vivax in the 1940s. They noted complete cure
required 10 ng/ml of plasma. Coatney et al. (34) measured
CQ levels after a 1.3-g regimen on day 35 and found them to
be 8, 9, and 19 ng/ml. These data represent the basis of the
widely cited MEC for P. vivax being 10 ng/ml and corroborate
the explanation given for the delayed relapses after CQ ther-
apy.
RATIONALE FOR IN VIVO DIAGNOSIS
Biological versus clinical resistance. A single dose of 0.3 g
of CQ or a level in blood plasma 10 ng/ml should achieve
complete cure of blood-stage CQ-sensitive P. vivax. An infec-
tion that persists in the face of these exposures to drug may be
classified biologically resistant. However, no one recommends
that vivax malaria be treated with just 0.3 g of CQ. Standard
therapy delivers five times that dose, and failure of that regi-
men constitutes clinical resistance. However, the tidy separa-
tion of biological and clinical resistance is difficult with P. vivax.
Clinicians wonder if the standard 1.5-g CQ regimen eliminates
parasitemia. If not, infection survived the towering drug con-
centrations following therapy (approximately 200 ng/ml of
plasma). This is clinical resistance. In contrast, a parasite
emerging from the liver and penetrating waning levels of drug
above 10 ng/ml of plasma is biologically resistant. Although
spared the immediate spike of drug soon after therapy, relaps-
ing parasites would nonetheless have been killed if they were
sensitive (Fig. 3).
Recrudescence versus reinfection and relapse. Molecular
biological assays classify genotypes of P. vivax and distinguish
reinfection from relapse (26, 40, 67). However, distinguishing
recrudescence from reinfection or relapse represents the crit-
ical need in analyzing the therapeutic response. The methods
of genetic analysis available at present do not allow this. A
genetic match between isolates causing primary and secondary
parasitemias does not prove recrudescence because hypnozo-
ites often derive from the genotype of the reference isolate
causing parasitemia (40, 67). Mismatch is also ambiguous: it
may be a reinfection or a relapse originating from hypnozoites
of a distinct genotype or a recrudescence of a minority geno-
type not originally detected. No method available at present
allows the unambiguous classification of P. vivax parasitemias
originating from recrudescence, relapse, or reinfection. Mul-
tilocus genotyping may ultimately bring clarity to this issue (6).
Sensitive versus resistant. The detection of CRPV does not
require relapse, reinfection, and recrudescence to be distin-
guished (13). A recurrent parasitemia, regardless of origin,
should not occur within 35 days of standard CQ therapy (Fig.
1). Parasitemia before 35 days penetrated an ordinarily lethal
exposure to CQ. Parasitemia clearing within 4 days and not
reappearing in 35 days may be classified as sensitive.
Clinicians and health policy makers want to know when
“resistant” parasites survived therapy or merely penetrated
waning levels of drug. The question is not academic. If para-
sites routinely survive a therapeutic intervention, it must be
changed. If parasites instead relapse only after successful ther-
apy, the problem may be attacked with primaquine. The clas-
sification explained here allows no such distinction. The anal-
ysis nonetheless provides key insights that help guide
treatment decisions.
Parasites classified as resistant either persisted for 4 days or
cleared but reappeared within 35 days. Persistent parasitemia
after 4 days represents the highest grade of clinical resistance,
whereas parasitemia recurring late (e.g., 30 days) is probably a
relapse in which the isolates penetrated drug levels close to the
MEC. The day of recurrence offers a scale upon which relative
resistance may be gauged. Parasites penetrating higher drug
levels soon after therapy are empirically more resistant than
parasites that penetrate lower drug levels later. Clinicians and
health policy makers may consider the proportion classified as
resistant and the median day of recurrence indicators of the
degree of resistance in the parasite population.
EVIDENCE SUPPORTING IN VIVO DIAGNOSIS
Recurrent parasitemia within 35 days of CQ therapy sup-
ports a provisional diagnosis of resistance. Confirmation re-
quires proof of adequate compliance to and absorption of
therapy by reliable supervision or, ideally, by determination of
the levels of drug in blood. Figure 3 illustrates data derived
from clinical trials with supervised dosing and ascertainment of
drug levels. Counterfeit drug, poor compliance, and emesis
FIG. 3. Cumulative incidence of relapses (left y axis) of P. vivax
infections after blood schizonticidal therapy with quinine (solid points)
or CQ (hollow points) during clinical trials conducted during the
1940s. Data were gathered from various sources (5, 33, 41, 58, 80, 92,
112, 114). The dotted curve represents hypothetical CQ drug levels
(right y axis) declining to below the MEC of approximately 100 ng/ml,
marked by the hashed line parallel to the x axis.
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may prevent normal drug levels from being achieved. An un-
ambiguous diagnosis of CRPV infection requires the demon-
stration of parasitemia with ordinarily effective drug levels
(10 ng/ml of plasma).
The blood challenge experiments of Berliner et al. (20) pro-
vided a definitive MEC for CQ-sensitive P. vivax. After CQ
treatment the relapse pattern with the plasma drug levels (Fig.
3) corroborated the estimate of the MEC. Two issues must be
considered today when the MEC is applied to present assess-
ments of CQ treatment effectiveness: (i) the analytical methods
of the 1940s and (ii) plasma CQ levels versus whole-blood CQ
levels.
Most laboratories have adopted the extraction and high-
pressure liquid chromatography procedures described by
Patchen et al. (86). This method quantifies CQ and its major
metabolite, desethylchloroquine (DCQ), in whole blood col-
lected onto filter paper. This medium spares the need for
centrifugation and a cold chain, a key advantage in the setting
of the rural tropics.
Early analytical methods did not discriminate between CQ
and DCQ (25, 77). The 10-ng/ml MEC represents the sum of
the plasma CQ and DCQ concentrations. In vitro studies with
CQ-sensitive P. falciparum consistently reveal that CQ and
DCQ have roughly equal antimalarial activities (54, 57, 108).
In gauging adequate exposure to drug in the bloodstream, the
sum of the CQ and DCQ concentrations is the operative sta-
tistic. The ratio of the CQ concentration to the DCQ concen-
tration has no clear bearing on the interpretation of this ques-
tion, except that a very low DCQ concentration relative to the
CQ concentration (e.g., the ratio of the CQ concentration to
the DCQ concentration  10) suggests contamination of the
sample with CQ dust.
The level of CQ-DCQ in whole blood corresponding to 10
ng/ml of plasma must be estimated to obtain a MEC in whole
blood. Several studies measured CQ and DCQ concentrations
in whole blood and plasma (2, 21, 47, 59, 96). The ratio of the
concentration in whole blood to the concentration in plasma
ranged from 5 to 10 (median, 8), yielding an estimated MEC in
whole blood of 75 to 150 ng/ml. These values agree with those
occurring 30 to 35 days after therapy, when relapse commences
(Fig. 1). Rombo et al. (95) deduced an MEC of 90 ng/ml of
whole blood for P. vivax among subjects taking CQ prophy-
laxis. A 100-ng/ml MEC for CQ-DCQ in whole blood against
CQ sensitive P. vivax was adopted (13).
Recurrent parasitemia within 35 days of therapy with 100
ng of CQ-DCQ per ml in whole blood demonstrates resistance
to CQ. A test duration of 28 days was recommended (13) to
accord with the standard World Health Organization test for P.
falciparum. The in vivo assessment represents a direct and
often convenient means of detecting resistance.
OTHER APPROACHES TO DIAGNOSING RESISTANCE
Experimental animals. Some nonhuman primate host-
adapted strains of P. vivax have been evaluated. Collins and
colleagues (36, 37) studied two strains of P. vivax acquired
from patients in Indonesia who failed CQ therapy. The ther-
apeutic profiles of CQ among well-characterized strains in
humans provide a basis for the classification of wild isolates as
sensitive or resistant in animal models. Collins et al. (36) dis-
cussed the rationale for classifying the CQ susceptibilities of
strains of P. vivax in Aotus or Saimiri monkeys. They point to
variations in the minimal therapeutic doses for strains known
to be sensitive to CQ in humans: Vietnam Palo Alto (18 mg),
Achiote (10 mg), and Chesson (9 mg). CQ-resistant Indone-
sian strain CDC I failed to be eradicated with 15 mg and was
classified as “possibly even more resistant than the Vietnam
Palo Alto strain.” The other strain from Indonesia failed to be
eradicated with 30 mg and was classified as resistant (37).
In vitro methods. The diagnosis of resistance to P. falcipa-
rum in vitro has been standard procedure since the 1970s.
Although P. vivax has not been cultivated continuously, it de-
velops for periods sufficient to assess the therapeutic response.
Methods for doing so have been described since the 1970s (24,
55, 90, 93), and there is renewed interest in these techniques
(60, 68, 98, 103, 104). No standard criteria for classifying in
vitro responses as sensitive or resistant yet exist. However,
many isolates have been characterized in Thailand, where the
clinical responses to CQ treatment remain uniformly sensitive.
This provides a baseline for in vitro sensitivity: 50 ng/ml
consistently inhibits development by 50%. In vitro testing for
CRPV may prove useful among well-equipped laboratories.
Molecular probes. No genetic mutations have been linked to
resistance to CQ by P. vivax. Nomura et al. (83) investigated
mutations in the P. vivax ortholog of the crt gene of P. falci-
parum, which has been linked to CQ resistance. The mutations
incriminated in P. falciparum crt did not occur among CRPV
isolates, and no other mutations in that gene correlated with
the phenotype. The genetic determinants of resistance to CQ
apparently differ between P. vivax and P. falciparum. Contin-
uous cultivation allowed the search for crt mutants in P. falci-
parum, and similar progress for P. vivax may be difficult; but
genomic analyses (46) may ultimately yield genetic determi-
nants of resistance.
Prophylaxis and cross-sectional studies. Among 94 study
subjects taking supervised CQ prophylaxis (5 mg/kg of body
weight weekly) in Indonesian New Guinea for 18 or 52 weeks,
29% developed P. vivax infections (11, 48), a rate indistinguish-
able from that for a placebo group (48). Among 41 subjects in
the same region evaluated in two other studies (8, 81), 61%
developed vivax malaria. Vivax malaria occurring during su-
pervised prophylaxis proves resistance to CQ.
Cross-sectional analyses of CQ levels may help gauge en-
demic resistance. Collection of blood on dried filter paper and
stained blood films (and later analysis in a laboratory) allow
assessment of hundreds of people with just a single day on-site,
whereas in vivo assessments require at least 1 month on-site.
This approach requires caution, however. A patient reporting
to a clinic with concentrations in blood greater than the MEC
may have recently self-administered drug, and even sensitive P.
vivax may take 4 days to clear. Nonetheless, the proportion of
patients infected with P. vivax and having concentrations in
blood greater than the MEC provides an estimate of the risk of
resistance (14).
GEOGRAPHIC RANGE OF RESISTANCE
Oceania. The data from Oceania come from just six infec-
tions acquired in Papua New Guinea, and no new report has
appeared in the past 10 years. Nonetheless, the risk of thera-
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peutic failure is considered high on the basis of the weight of
the data from Indonesian New Guinea (see below and Table
1). Moreover, unpublished data (99a) revealed therapeutic
failure rates from 0 to 33% in the late 1980s. Surveys of ther-
apeutic responses to CQ throughout Oceania are needed.
East Asia. Six East Asian nations have reported data on
CRPV: Indonesia, Malaysia, Myanmar, Thailand, Vietnam,
and Philippines. The data from Indonesia span 1992 to 2002
and reveal a high risk in the eastern archipelago. The risk in
the far eastern province of Papua is highest. Among 41 subjects
taking supervised prophylaxis, 61% developed vivax malaria (8,
81), as did 29% (the same rate as the placebo group) in two
other studies (11, 48). Among 88 subjects treated up to 1995,
41% had a response consistent with resistance (8, 81). Among
282 subjects evaluated since then, 39% were infected with
resistant isolates (9, 11, 48, 52, 102, 106). However, all 38
subjects evaluated on a small, isolated island in Papua had
infections with sensitive organisms (52). In western Indonesia
two separate surveys at Nias, near northern Sumatra, found 9
inadequate responses among 49 subjects (18%) (16, 50). A
survey of 54 subjects in Indonesian Borneo revealed that 22%
of the isolates were CRPV (53). Surveys at Lombok (west of
Bali) and central Java in the early 1990s found no resistance
among isolates from 20 and 14 subjects, respectively (15, 49).
However, the site in central Java was reevaluated in 2001, and
among 77 subjects, 14 (18%) were infected with CRPV (75). A
traveler to Flores in the Lesser Sundas archipelago had CRPV
infection (61).
CPRV is endemic in Malaysia, Myanmar, and Vietnam. A
traveler to Sabah in Malaysian Borneo (1) presented with vivax
malaria in Sweden with ordinarily protective CQ levels in
blood. Among a series of 60 patients hospitalized in Kuala
Lumpur (1983 to 1992), 6 were described as infected with
CRPV (66). CRPV has been confirmed in Myanmar: Myat-
Phone-Kyaw et al. (82) presented two case reports, and a
survey of 50 patients (76) revealed that 14% were infected with
CRPV. A study of 23 subjects in Vietnam in 1995 revealed no
CRPV (105), but recently, 28 of 113 (25%) subjects had re-
current P. vivax infections by day 28 after treatment (87).
There is no evidence of CPRV from Thailand, Cambodia,
Laos, China, the Korean Peninsula, or the Philippine archipel-
ago. However, Thailand represents the only one of these na-
tions in which adequate surveys have been conducted (38, 72,
103): 1,046 subjects were reliably evaluated, and only 4 (0.4%)
had recurrent parasitemia within 28 days after infection (and
these responded to a second round of CQ therapy). No reports
of CQ efficacy against P. vivax were found from Cambodia,
Laos, China, or the Koreas. At Palawan in the Philippines,
Baird et al. (10) evaluated 21 P. vivax infections and none
recurred within 28 days.
South Asia. Only seven cases of CRPV have been reported
from India (42, 44, 56, 89, 69). The only other study from
southern Asia comes from Iran: Hamedi et al. (60) evaluated
39 subjects, and none had a recurrent parasitemia within 28
days.
South America. Phillips et al. (88) reported on the presence
of CPRV in three travelers to Guyana repatriated to Canada.
Baird et al. (17) evaluated 32 subjects in Guyana with vivax
malaria, and none had recurrent parasitemia within 28 days.
Likewise, Castillo et al. (30) and Villalobos-Salcedo et al. (109)
evaluated 44 and 73 subjects in Columbia and Brazil, respec-
tively, and none had recurrent parasitemia within 28 days.
Machado et al. (74) evaluated 30 subjects infected near Belem
in Brazil; the infection was cleared from all subjects by day 4,
and none had a recurrence by day 30. However, Soto et al.
(101) described three cases of CRPV infection among 27 sub-
jects in Colombia, and Alecrim et al. (4) described a single case
from Amazonia. Ruebush and colleagues (97) confirmed four
cases of CRPV infection among 177 (2%) infected subjects
evaluated in the Amazon region of Peru. CRPV apparently
occurs in the New World but at a low frequency (risk, probably
5%).
ALTERNATIVE THERAPIES
Mefloquine. Some authorities recommend mefloquine for
therapy for CRPV (29, 78). No clinical data yet support that
recommendation. Mefloquine proved effective against CQ-re-
sistant P. falciparum and was effective against CQ-sensitive P.
vivax (3, 43, 62). Good efficacy against CRPV seems a reason-
able supposition, and Collins et al. (37) demonstrated that
mefloquine had good efficacy against an Indonesian CRPV
strain in Aotus monkeys. However, work by Nomura et al. (83)
points to different mechanisms of resistance between the two
species, and caution is warranted.
Indirect evidence suggests that mefloquine may be effica-
cious against CRPV. Ohrt et al. (85) demonstrated the com-
plete efficacy of mefloquine for prophylaxis against the CRPV
strain known to occur in northeastern Indonesian New Guinea.
However, they also found that daily doxycycline had complete
efficacy against CRPV, and Taylor et al. (106) showed doxycy-
cline monotherapy to have only 33% efficacy against CRPV.
Clinical trials of mefloquine against CRPV are needed.
Halofantrine, CQ plus doxycycline, or primaquine. Taylor et
al. (106) evaluated CQ and doxycycline combined in Indonesia
and found 71% efficacy. This was superior to the 29 and 33%
efficacies of the respective monotherapies against vivax malaria
but was inferior to the 91% efficacy of the combination against
P. falciparum. Baird et al. (9) evaluated halofantrine mono-
therapy and CQ combined with primaquine against P. vivax in
Indonesian New Guinea. CQ combined with primaquine (10
mg/kg over 2 weeks or 2.5 mg/kg over 48 h) provided superior
efficacy in 79 patients (87%) relative to the efficacy of CQ
monotherapy in 50 patients (30%). Halofantrine monotherapy
cured all 19 subjects treated, although there was one recur-
rence on day 28 after the end of treatment.
Phillips et al. (88) used CQ (25 mg/kg over 2 days) and
primaquine (2.5 mg/kg over 2 days) in three patients with
CRPV infections acquired in Guyana. They described this
therapy as inadequate because two patients had recurrent par-
asitemia after 6 weeks. However, the abbreviated primaquine
regimen was not intended to prevent relapse but to clear the
bloodstream, and it apparently achieved this in all three pa-
tients. The best combination of CQ plus primaquine may be 0.5
mg of primaquine/kg daily for 14 days or 1.0 mg of prima-
quine/kg daily for 7 days. This regimen clears the bloodstream
of CRPV and would prevent relapse. It should not be used for
patients likely to be infected with P. falciparum as well, because
it has no efficacy against that type of infection (19).
VOL. 48, 2004 MINIREVIEW 4079
 
TABLE 1. Summary of recently reported CQ sensitivity or resistance by P. vivax
Region Country Area Yr No. of infectionsexamined
No. of resistant
infectionsa Use of drug
b Reference
Oceania Papua New Guinea East New Britain 1989 2 2 Rx 94
Not specified 1989 1 1 Rx 111
Madang/Lae 1991 1 1 Rx 35
New Britain 1992 1 1 Rx 35
Madang and Lae 1992 2 2 Rx 99
Southeast Asia Indonesia Arso, Papua 1992 24 16 Px 8
Arso, Papua 1992 1 1 Rx and Px 8
Nias, Sumatra 1992 1 1 Rx and Px 100
Arso, Papua 1993 46 10 Rx 81
Arso, Papua 1993 17 9 Px 81
Arso, Papua 1995 50 35 Rx 9
Arso, Papua 1995 54 12 Px 11
Arso, Papua 1995 40 15 Px 48
Menoreh Hills, Java 1996 14 0 Rx 15
Nias, Sumatra 1996 21 3 Rx 16
Nabire, Papua 1996 34 18 Rx 18
Arso, Papua 1997 49 42 Rx 102
Western Lombok 1997 20 0 Rx 49
Western Borneo 1998 54 12 Rx 53
Northern Sulawesi 1998 11 1 Rx 51
Lesser Sundas 1998 1 1 Rx 61
Gag Island, Papua 1999 38 0 Rx 52
Jayapura, Papua 2001 17 5 Rx 106
Nias, Sumatra 2002 28 6 Rx 50
Menoreh Hills, Java 2002 77 14 Rx 75
Malaysia Sabah, Borneo 1996 1 1 Rx and Px 1
Urban composite 1998 60 6 Rx 66
Myanmar Mine Pyin and Pwint Phyu 1993 2 2 Rx 82
Mingaladon 1995 50 7 Rx 76
Thailand Bo Rai 1991 77 0 Px 23
Chantaburi 1995 57 0 Rx 103
Urban composite 1999 886 4 Rx 72
Sa Kaeo 2002 26 0 Rx 38
Vietnam Na Trang 2000 23 0 Rx 105
Not specified 2002 120 28 Rx 87
Philippines Palawan 1996 21 0 Rx 10
South Asia Iran Bandar Abbas 2002 39 0 Rx 60
India Bombay 1995 2 2 Rx 56
Bombay 1995 7 1 Rx 89
Calcutta 1995 1 1 Px and Rx 107
Mathura 1996 1 1 Rx 44
Bombay 2000 1 1 Rx 69
Bombay 2003 1 1 Rx 42
South America Guyana Interior 1996 3 3 Rx 88
Interior 2002 32 0 Rx 17
Colombia Llanos Orientales/Uraba 2001 27 3 Rx 101
Cali 2002 44 0 Rx 30
Brazil Manaus 1999 1 1 Rx 4
Rondonia 2000 73 0 Rx 109
Belem 2003 30 0 Rx 74
Peru Amazonia 2003 177 4 Rx 97
a Classified as resistant by the reporting authors.
b Rx, standard treatment; Px, standard prophylaxis.
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Malarone. Lacy et al. (70) evaluated Malarone (250 mg of
atovaquone and 100 mg of proguanil daily for 3 days; Glaxo-
SmithKline, London, United Kingdom) in 16 subjects with P.
vivax infections in Indonesian New Guinea. They also received
0.5 mg of primaquine/kg daily for 14 days. All subjects cleared
the fever and parasitemia by day 3 and remained free of par-
asitemia for 28 days. Malarone combined with primaquine is
the only available therapy with proven efficacy (90%) against
CRPV, but that finding is from the results of a study with just
16 patients.
Tafenoquine. Tafenoquine (GlaxoSmithKline) is an 8-ami-
noquinoline analog of primaquine that has potent schizonti-
cidal activity against P. vivax and P. falciparum in tissue and
blood and that is now in clinical trials. This drug has been
demonstrated to be effective against CRPV in nonhuman pri-
mates (39, 84).
Sulfadoxine-pyrimethamine. Recent work by Hastings and
Sibley (63) suggests that P. vivax may be susceptible to antifo-
late inhibitors of dihydrofolate reductase (DHFR). DHFR
mutations in P. vivax are apparently responsible for the lack of
activity among the antifolates. Hastings et al. (64) also found
that quadruple mutations in dihydrofolate reductase corre-
sponded to the therapeutic failure of sulfadoxine-pyri-
methamine treatment among patients with P. vivax infections
acquired in Indonesia. When quadruple P. vivax dhfr mutants
do not occur, sulfadoxine-pyrimethamine may be useful
against CRPV, but clinical trials are needed.
CONCLUSIONS
Infections with CQ-sensitive P. vivax were routinely cured
with as little as 0.3 g of CQ base, even though 1.5 g has been
the recommended therapy since 1946. The clinical failure of
standard therapy therefore represents infection with an organ-
ism with a high degree of resistance. A persistent or recurrent
parasitemia within 14 days of the start of treatment probably
represents recrudescence by a highly resistant strain of P. vivax.
A recurrent parasitemia between 15 and 35 days after the start
of treatment with 100 ng of CQ-DCQ per ml is resistant to
CQ, regardless of whether that parasitemia originates from a
relapse, a reinfection, or a recrudescence. In general, the day
of recurrence correlates inversely with degree of resistance, but
isolates that cause recurrences after CQ and DCQ levels fall
below the MEC (at about day 35) cannot be classified as
sensitive or resistant. When 30 mg of CQ base against P. vivax
in Aotus monkeys fails, the organism may be classified as re-
sistant. When 50 ng of CQ base/ml fails to inhibit in vitro
schizont development by more than 50%, the isolate may be
classified as resistant. CRPV appears to be most common in
eastern Indonesia, especially on the island of New Guinea. It
appears sporadically elsewhere in Southeast Asia, typically
among 15% of strains. No cases of CRPV infection have yet
occurred in Thailand. The data supporting alternative thera-
pies for CRPV are scanty. A small trial of Malarone combined
with primaquine in Indonesian New Guinea may be the best
available evidence of the good efficacy of this agent against
CRPV.
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